newsfilter
← Latest News
PR Newswire·

European Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New Strategy

JERUSALEM, March 14, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced today that it had been negotiating with the European Investment Bank (the "EIB") terms of restructuring of its outstanding €24 million loan (the "Loan"). T